个人简介：

田君，博士，南方科技大学医学院助理教授（独立PI）、副研究员，博士生导师。2018年博士毕业于加拿大麦吉尔大学，2019-2023年在美国哈佛医学院麻省总医院从事博士后研究。2023年8月加入南方科技大学医学院。主要研究领域为癌症的靶向和免疫治疗，在寻找药物耐药性的机制，研究和开发新的联合治疗策略，肿瘤类器官模型的建立和药物测试等方面取得了一系列成果。近年来共发表SCI论文十余篇，其中第一作者论文发表于Nature Medicine、British Journal of Cancer、Breast Cancer Research等国际高水平期刊杂志。曾获得麦吉尔大学优秀博士毕业生奖项，以及美国国立卫生院和哈佛癌症中心研究基金一项。担任杂志Frontiers in Genetics审稿人，以及美国癌症研究协会会员。

教育背景：

2009-2013 南开大学，学士

2013-2018 加拿大麦吉尔大学，博士

工作经历：

2023.08-至今 南方科技大学医学院，助理教授

2019-2023 美国哈佛医学院麻省总医院，博士后

2018-2019 加拿大麦吉尔大学健康中心，博士后

获奖情况及荣誉：

2018 加拿大麦吉尔大学优秀博士毕业生奖

2017 加拿大麦吉尔大学医学院优秀生产力奖

研究领域：

基础研究：（1）研究致癌信号通路对肿瘤免疫微环境的影响；（2）研究肿瘤的靶向药和免疫治疗的协同作用；（3）肿瘤靶向药物的耐药机制。以消化道肿瘤，胰腺癌等为主要研究癌种。

临床转化应用研究：通过发现新的肿瘤靶向药和免疫治疗的应答/耐药机制，设计针对不同突变型（如KRAS突变）患者的药物联合治疗方案；寻找患者对药物联合治疗反应/耐药的生物标记物。

人源肿瘤类器官模型的建立：肿瘤药物的疗效评估、机制研究和生物标志物的发现。

学术任职：

杂志Frontiers in Genetics审稿人

美国癌症研究协会会员

发表论文：

1. Jun Tian; Jonathan H. Chen; Sherry X. Chao; Karin Pelka; Marios Giannakis; Julian Hess; Kelly Burke; Vjola Jorgji; Princy Sindurakar; Jonathan Braverman; Arnav Mehta; Tomonori Oka; Mei Huang; David Lieb; Maxwell Spurrell; Jill N. Allen; Thomas A. Abrams; Jeffrey W. Clark; Andrea C. Enzinger; Peter C. Enzinger; Samuel J. Klempner; Nadine J. McCleary; Jeffrey A. Meyerhardt; David P. Ryan; Matthew B. Yurgelun; Katie Kanter; Emily E. Van Seventer; Islam Baiev; Gary Chi; Joy Jarnagin; William B. Bradford; Edmond Wong; Alexa G. Michel; Isobel J. Fetter; Giulia Siravegna; Angelo J. Gemma; Arlene Sharpe; Shadmehr Demehri; Rebecca Leary; Catarina D. Campbell; Omer Yilmaz; Gad A. Getz; Aparna R. Parikh; Nir Hacohen; Ryan B. Corcoran ; Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial, Nature Medicine, 2023, 29: 458-466

2. Yi Sun; Or-yam Revach; Seth Anderson; Emily A. Kessler; Clara H. Wolfe; Anne Jenney; Caitlin E. Mills; Emily J. Robitschek; Thomas G. R. Davis; Sarah Kim; Amina Fu; Xiang Ma; Jia Gwee; Payal Tiwari; Peter P. Du; Princy Sindurakar; Jun Tian; Arnav Mehta; Alexis M. Schneider; Keren Yizhak; Moshe Sade-Feldman; Thomas LaSalle; Tatyana Sharova; Hongyan Xie; Shuming Liu; William A. Michaud; Rodrigo Saad-Beretta; Kathleen B. Yates; Arvin Iracheta-Vellve; Johan K. E. Spetz; Xingping Qin; Kristopher A. Sarosiek; Gao Zhang; Jong Wook Kim; Mack Y. Su; Angelina M. Cicerchia; Martin Q. Rasmussen; Samuel J. Klempner; Dejan Juric; Sara I. Pai; David M. Miller; Anita Giobbie-Hurder; Jonathan H. Chen; Karin Pelka; Dennie T. Frederick; Susanna Stinson; Elena Ivanova; Amir R. Aref; Cloud P. Paweletz; David A. Barbie; Debattama R. Sen; David E. Fisher; Ryan B. Corcoran; Nir Hacohen; Peter K. Sorger; Keith T. Flaherty; Genevieve M. Boland; Robert T. Manguso; Russell W. Jenkins ; Targeting TBK1 to overcome resistance to cancer immunotherapy, Nature, 2023, 615(7950): 158-167

3. Tian, Jun; Wang, Vivian; Wang, Ni; Khadang, Baharak; Boudreault, Julien; Bakdounes, Khldoun; Ali, Suhad; Lebrun, Jean-Jacques ; Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition, BREAST CANCER RESEARCH, 2021, 23(1)

4. Shams, Anwar; Binothman, Najat; Boudreault, Julien; Wang, Ni; Shams, Fuad; Hamam, Dana; Tian, Jun; Moamer, Alaa; Dai, Meiou; Lebrun, Jean-Jacques; Ali, Suhad ; Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis, ONCOGENESIS, 2021, 10(1)

5. Jun Tian; Fatmah Al Raffa; Meiou Dai; Alaa Moamer; Baharak Khadang; Ibrahim Y.Hachim; Khldoun Bakdounes; Suhad Ali; Bertrand Jean-Claude; Jean-Jacques Lebrun ; Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells, British Journal of Cancer, 2018, 119(12): 1495-1507

6. Jun Tian; Amal A.Al-Odaini; Yun Wang; Juliana Korah; Meiou Dai; Lan Xiao; Suhad Ali; Jean-Jacques Lebrun ; KiSS1 gene as a novel mediator of TGFβ-mediated cell invasion in triple negative breast cancer, Cellular Signalling, 2018, 42: 10

7. Jun Tian; Mahmood Y.Hachim; Ibrahim Y.Hachim; Meiou Dai; Chieh Lo; Fatmah Al Raffa; Suhad Ali; Jean Jacques Lebrun ; Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triplenegative breast cancer, Scientific Reports, 2017, 7: 40258

8. Hongru Zhang; Zheng Li; Li Wang; Gaofei Tian; Jun Tian; Zishan Yang; Guangchao Cao; Hong Zhou; Liqing Zhao; Zhenzhou Wu; Zhinan Yin ; Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function, Frontiers in Immunology, 2017, 8(129)

9. Laure Humbert; Mostafa Ghozlan; Lucie Canaff; Jun Tian; Jean-Jacques Lebrun ; The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma, BMC Cancer, 2015, 15(1): 200

10. Jimin Guo; Lucie Canaff; Charles Vincent Rajadurai; Nadège Fils-Aimé; Jun Tian; Meiou Dai; Juliana Korah; Manuel Villatoro; Morag Park; Suhad Ali; Jean-Jacques Lebrun ; Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes, Breast Cancer Research, 2014, 16(6): 476